Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies. - Wikidata - wikimedia - TriplyDB

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.

http://www.wikidata.org/entity/Q33428775

about

Advances in emerging drugs for the treatment of neuroblastoma.Anti-angiogenesis target therapy for advanced osteosarcoma (Review).

P2860

Q39158415-EA5FC7A3-D177-4401-89F8-9E166961EE79 Q39401628-18D46DFE-B20D-4428-AC37-B89A436B86A0

P2860

Pediatric phase I trial of oral sorafenib and topotecan in refractory or recurrent pediatric solid malignancies.

http://www.wikidata.org/entity/Q33428775

description

2015 nî lūn-bûn

@nan

2015 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Pediatric phase I trial of ora ...... pediatric solid malignancies.

@ast

Pediatric phase I trial of ora ...... pediatric solid malignancies.

@en

type

label

Pediatric phase I trial of ora ...... pediatric solid malignancies.

@ast

Pediatric phase I trial of ora ...... pediatric solid malignancies.

@en

prefLabel

Pediatric phase I trial of ora ...... pediatric solid malignancies.

@ast

Pediatric phase I trial of ora ...... pediatric solid malignancies.

@en

P1433

Q33428775-BDC181B0-0F52-46C7-B39D-7EC22D5D0F0D

P1476

Q33428775-93820791-3FE3-4D45-AAAE-35E25E66558B

P2093

Q33428775-03ECBE73-CD81-444E-8304-F4D99F35151E

Q33428775-116755FA-F8E0-4468-8EA0-328C454AB949

Q33428775-1A63A3FA-DA1C-4D7A-AAB2-5C66A7C8A27D

Q33428775-22695F3B-5D10-472D-8A30-93435C61A56A

Q33428775-38B01263-65BB-4AC8-939C-C4AD4B6EF6D7

Q33428775-43A56B0D-25CA-4C0B-87F8-A74DEA0A53BD

Q33428775-60260303-C343-4B4C-8AAA-B19B3D67926A

Q33428775-624A07B0-6D9E-4695-BA37-2FD61770C38A

Q33428775-72857298-F20D-4EFE-903E-113E7AA64D2D

Q33428775-B0F7158B-AFF3-4E1D-BD65-915F22510813

P2860

Q33428775-02E8F9E3-27D8-48FE-92AE-7616A92983A0

Q33428775-079492B8-7822-4E26-AA39-73B5423CEEAF

Q33428775-0C241E11-EC8B-4E96-8792-826443DAB0D8

Q33428775-21F2D778-B104-46D1-B022-54513BD04087

Q33428775-226AA919-8D88-4019-8D74-21B7DE00B1EE

Q33428775-2B5ED9BF-FCF2-4608-992A-912CDC5EB9AC

Q33428775-2EFBFF7F-AFA2-44D4-9F2C-B8AFFA45B67C

Q33428775-40BDAF6C-17E4-480E-997E-5ACC94BCCBFF

Q33428775-49FD33D1-994C-48A1-BD2E-620F99FE2CDC

Q33428775-4F784C50-7D15-4B57-BAD9-E597EDFAD290

P304

Q33428775-BD8C5FEC-277C-4134-916C-B38D02990812

P31

Q33428775-8B717441-2C84-4EC6-8257-1988C5B85923

P356

Q33428775-FFF35802-78C5-473C-86F6-CF59B4097AEC

P407

Q33428775-EDE318A4-0045-4797-B256-238F41759316

P433

Q33428775-FFC0A7E5-4392-42AA-8752-C8C1D298412A

P478

Q33428775-2A30AFBF-F796-440E-9A84-EDD260F4D044

P50

Q33428775-B2FBACDF-219F-47CA-A1F6-EE91200EE0D9

P577

Q33428775-36F3996E-0D66-4474-9882-B4A24B9B9401

P5875

Q33428775-26EA1AD6-B174-438D-A9BC-7A14054C320C

P698

Q33428775-C4ACEC28-B4EA-4D89-BF9E-B63228EAEACF

P921

Q33428775-0E1765A9-8B7C-4EE0-A99E-D72E0645210F

P932

Q33428775-F1C65199-7EE9-4229-B1B0-159B6477E159

P356

P1433

Cancer Medicine

P1476

Pediatric phase I trial of ora ...... pediatric solid malignancies.

@en

P2093

Anthony M Neuger

http://www.w3.org/2001/XMLSchema#string

Daniel M Sullivan

http://www.w3.org/2001/XMLSchema#string

Eric Sandler

http://www.w3.org/2001/XMLSchema#string

Gregory A Hale

http://www.w3.org/2001/XMLSchema#string

Jae K Lee

http://www.w3.org/2001/XMLSchema#string

Jamie Caracciolo

http://www.w3.org/2001/XMLSchema#string

John Goldberg

http://www.w3.org/2001/XMLSchema#string

Jonathan Gill

http://www.w3.org/2001/XMLSchema#string

Kathleen Manning

http://www.w3.org/2001/XMLSchema#string

Leo Mascarenhas

http://www.w3.org/2001/XMLSchema#string

P2860

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

Activity of Sorafenib against desmoid tumor/deep fibromatosis

Children's Oncology Group's 2013 blueprint for research: renal tumors

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

Phase I and pharmacokinetic study of topotecan administered orally once daily for 5 days for 2 consecutive weeks to pediatric patients with refractory solid tumors.

Topotecan is active against Wilms' tumor: results of a multi-institutional phase II study.

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium report.

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.

Final report of phase II study of sorafenib, cytarabine and idarubicin for initial therapy in younger patients with acute myeloid leukemia

P304

294-303

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CAM4.598

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-12-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

288830998

http://www.w3.org/2001/XMLSchema#string

P698

26714427

http://www.w3.org/2001/XMLSchema#string

P921

phase I clinical trial

P932

4735769

http://www.w3.org/2001/XMLSchema#string